Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Additionally, adoption of the drugs will grow as more medical professionals recommend them to manage obesity
What Clinical Trials Show In large obesity trials: Average weight loss is ~15% of starting body weight with semaglutide 2.4 mg Average weight loss is ~2022% of starting body weight with tirzepatide 15 mg The majority of weight loss occurs within the first year of treatment Plateaus are common after significant weight reduction Some people lose more, some less but a flattening of the weight-loss curve is expected , especially after meaningful progress has already occurred
Food and Drug Administration (FDA) reports that it is found in over 600 medications, including cold and flu treatments, increasing its widespread accessibility
J Clin Invest 49(4):837848
